Financial Strategies Acquisition Corp. (FXCOW) is a blank check company whose sole purpose is to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, with a focus on the financial technology and financial services sectors. Incorporated in 2020 and headquartered at 2626 Cole Avenue, Suite 300, Dallas, Texas, the company has no significant operations or revenue generation and targets businesses primarily in financial services. In February 2023, it entered into a definitive business combination agreement with Austin Biosciences Corp., a Texas-based biotechnology platform company developing patent-protected cancer therapies capable of crossing the blood-brain barrier, valuing the pro forma entity at approximately $166.3 million assuming no redemptions; however, the transaction failed to close as scheduled in Q2 2023 amid high redemptions and regulatory delays. Facing its transaction deadline in December 2023, the company pursued multiple trust extensions and filed for Chapter 11 bankruptcy on December 6, 2023, in a bid to access trust funds for creditors including insiders, but a U.S. Bankruptcy Court ruling upheld the trust's exclusivity for public shareholders, leading to withdrawal of conversion to Chapter 7 liquidation; the case closed on July 30, 2024, with trust distributions prioritizing redeemed public shareholders. Nasdaq issued deficiency notices in 2023 for delayed filings, contributing to delisting proceedings for its warrants (FXCOW), which faced removal after partial redemptions and low trading volume, while the common stock (FXCO) trades over-the-counter amid ongoing short interest and liquidation aftermath.